PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBDatopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 …
All news | Pipelinereview
WEB5 days ago · PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - …
FDA Approves First Treatment for Niemann-Pick Disease, Type C
WEB11 hours ago · SILVER SPRING, MD, USA I September 20, 2024 I Today, the U.S. Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the …
Wegovy® recommended by the European regulatory authorities …
WEB19 hours ago · Wegovy ® (semaglutide 2.4 mg) is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and …
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as …
WEB11 hours ago · European Commission grants conditional marketing authorization for Iqirvo ® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare …
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron …
WEB11 hours ago · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct …
Vaccines | Pipelinereview
WEBSep 12, 2024 · HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, WA, USA I September 17, 2024 I HDT …
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for ...
WEB11 hours ago · OPUVIZ™, a biosimilar referencing Eylea 1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for …
VOYDEYA™ approved in the US as add-on therapy to
WEBApr 2, 2024 · Approval of first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial. WILMINGTON, DE, USA I April 01, 2024 I VOYDEYA™ …
Boehringer’s nerandomilast meets primary endpoint in pivotal …
WEB4 days ago · INGELHEIM, Germany I September 16, 2024 I Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was …